Jun 11, 2020
Real-World Data of Terlipressin in Hospitalized Patients in U.K. with Hepatorenal Syndrome Type 1 (HRS-1) Published in Alimentary Pharmacology and Therapeutics
Apr 22, 2020
Mallinckrodt Announces U.S. Food and Drug Administration (FDA) Filing Acceptance of New Drug Application for Terlipressin for Treatment of Hepatorenal Syndrome Type 1 (HRS-1)
Mar 17, 2020
Mallinckrodt Completes Rolling Submission of New Drug Application to the U.S. Food and Drug Administration (FDA) for Terlipressin for the Treatment of Patients with Hepatorenal Syndrome Type 1 (HRS-1)
Mar 02, 2020
Mallinckrodt Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration (FDA) for Terlipressin for the Treatment of Patients with Hepatorenal Syndrome Type 1 (HRS-1)
Nov 11, 2019
Mallinckrodt Presents Positive Phase 3 Results from its CONFIRM Study of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1) at The Liver Meeting® 2019
Oct 21, 2019
Mallinckrodt to Present Results from its Pivotal Phase 3 CONFIRM Study of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1) at The Liver Meeting® 2019
May 14, 2019
Mallinckrodt Completes Enrollment of Phase 3 Terlipressin CONFIRM Trial
Apr 15, 2019
Data on Impact of Revised Consensus Recommendations on Time to Treatment and Serum Creatinine (SCr) at Treatment Start for Patients with Hepatorenal Syndrome Type 1 (HRS-1) Presented at the 2019 International Liver Congress(TM) (EASL)
Nov 09, 2018
Mallinckrodt Presents Terlipressin Clinical Data at The Liver Meeting® 2018
Oct 23, 2017
Mallinckrodt Presents Health Economic Data Related to Hepatorenal Syndrome at The Liver Meeting® 2017, the Annual Meeting of the American Association for the Study of Liver Diseases
Jun 23, 2017
Health Economic Data on Burden of Hepatorenal Syndrome Published in Current Medical Research and Opinion